Q BioMed Inc. (QBIO) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QBIO representa a Q BioMed Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 57/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Q BioMed Inc. (QBIO) Resumen de Asistencia Médica y Tuberías
Q BioMed Inc. operates as a biomedical accelerator, acquiring and developing life science assets, including a marketed radiopharmaceutical for bone cancer pain and preclinical candidates targeting glaucoma, autism spectrum disorder, and liver cancer. The company focuses on unmet medical needs within the biotechnology sector.
Tesis de Inversión
Q BioMed Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's current marketed product, Strontium Chloride SR89, generates revenue, but the company's future growth depends heavily on the successful development and commercialization of its pipeline assets. Key value drivers include the advancement of Man-01 into clinical trials for glaucoma and positive clinical data for QBM-001 in autism spectrum disorder. The company's small size and limited resources pose significant risks, requiring careful monitoring of cash burn and potential dilution. The negative profit margin of -721.7% and gross margin of -3.2% highlight the company's current financial challenges. Investors should closely evaluate the clinical trial timelines and regulatory pathways for Q BioMed's pipeline candidates.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Q BioMed Inc. operates in the biotechnology sector, focusing on acquiring and developing life science assets.
- The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics for metastatic bone cancer pain.
- Q BioMed is developing Man-01 for primary open angle glaucoma, currently in the pre-clinical stage.
- The company is also developing QBM-001 for rare pediatric non-verbal autism spectrum disorder.
- Q BioMed has a partnership with Mannin Research Inc. to develop therapeutics for acute respiratory distress syndrome, glaucoma, and kidney diseases.
Competidores y Pares
Fortalezas
- Marketed products generating revenue (Strontium Chloride SR89 and Metastron).
- Diverse pipeline of preclinical candidates targeting multiple therapeutic areas.
- Partnership with Mannin Research Inc.
- Experienced management team in life sciences.
Debilidades
- Limited financial resources and high cash burn.
- Dependence on successful development of pipeline assets.
- Small team size and limited infrastructure.
- Negative profit and gross margins.
Catalizadores
- Upcoming: Initiation of Phase 1 clinical trials for Man-01 in glaucoma (projected by late 2026).
- Upcoming: Initiation of Phase 1 clinical trials for QBM-001 in autism spectrum disorder (projected by early 2027).
- Ongoing: Commercial expansion efforts for Strontium Chloride SR89 and Metastron.
- Ongoing: Evaluation and potential acquisition of new life science assets.
- Upcoming: Advancement of Uttroside-B to IND-enabling studies (projected by mid-2027).
Riesgos
- Ongoing: Limited financial resources and high cash burn rate.
- Potential: Clinical trial failures for pipeline candidates.
- Potential: Regulatory setbacks and delays in drug approval.
- Ongoing: Competition from established pharmaceutical companies.
- Potential: Product liability claims and intellectual property disputes.
Oportunidades de crecimiento
- Advancement of Man-01 for Glaucoma Treatment: The global glaucoma market is projected to reach $5.9 billion by 2027. Q BioMed's Man-01, a pre-clinical lead candidate, represents a significant growth opportunity if it successfully transitions into clinical trials and demonstrates efficacy. The company's partnership with Mannin Research Inc. could accelerate the development process. Timeline: Initiate Phase 1 trials by late 2026.
- Development of QBM-001 for Autism Spectrum Disorder: The market for autism spectrum disorder treatments is expanding, with increasing awareness and diagnosis rates. QBM-001 targets a specific subset of patients with rare pediatric non-verbal autism, offering a potentially targeted therapy. Positive pre-clinical data and successful Phase 1 trials could drive significant value. Timeline: Initiate Phase 1 trials by early 2027.
- Commercial Expansion of Strontium Chloride SR89 and Metastron: While already marketed, Strontium Chloride SR89 and Metastron offer opportunities for expanded commercialization through strategic partnerships and geographic expansion. Focusing on underserved markets and optimizing distribution channels could increase revenue. The market for bone cancer pain therapeutics is expected to grow steadily. Timeline: Ongoing efforts to expand market reach.
- Licensing and Acquisition of New Assets: Q BioMed's core strategy involves acquiring and licensing promising life science assets. Identifying and securing undervalued or under-resourced assets with strong potential could fuel future growth. A disciplined approach to due diligence and strategic partnerships is crucial. Timeline: Ongoing evaluation of potential acquisition targets.
- Development of Uttroside-B for Liver Cancer: The global liver cancer therapeutics market is expected to grow, driven by increasing incidence rates. Uttroside-B represents a potential new treatment option. Successful pre-clinical development and subsequent clinical trials are essential for realizing this growth opportunity. Timeline: Advance to IND-enabling studies by mid-2027.
Oportunidades
- Advancement of Man-01 into clinical trials for glaucoma.
- Positive clinical data for QBM-001 in autism spectrum disorder.
- Strategic partnerships for commercialization and development.
- Acquisition of new promising life science assets.
Amenazas
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Inability to secure funding for continued development.
- Product liability claims and intellectual property disputes.
Ventajas competitivas
- Proprietary drug formulations for Strontium Chloride SR89 and Metastron.
- Intellectual property rights for pipeline candidates like Man-01, QBM-001, and Uttroside-B.
- Established relationships with researchers and clinicians.
- Expertise in acquiring and developing undervalued life science assets.
Acerca de QBIO
Q BioMed Inc., established in 2013 and based in New York City, is a biomedical acceleration and development company. Originally named ISMO Tech Solutions, Inc., the company rebranded in July 2015 to reflect its focus on acquiring and developing promising life science assets. Q BioMed's core strategy involves licensing and acquiring undervalued or under-resourced life sciences and healthcare companies, providing them with the necessary resources to advance their development programs. The company's portfolio includes Strontium Chloride SR89 and Metastron, radiopharmaceutical therapeutics used for the treatment of metastatic bone cancer pain. Additionally, Q BioMed is actively developing a pipeline of preclinical candidates, including Man-01 for primary open angle glaucoma, QBM-001 for rare pediatric non-verbal autism spectrum disorder, and Uttroside-B for liver cancer. The company also has a partnership with Mannin Research Inc. to develop therapeutics for conditions such as acute respiratory distress syndrome, glaucoma, and kidney diseases. With a small team of 3 employees, Q BioMed operates with a lean structure, focusing on strategic partnerships and efficient resource allocation to advance its development programs.
Qué hacen
- Acquires and licenses life science and healthcare assets.
- Develops therapeutics for unmet medical needs.
- Markets Strontium Chloride SR89 and Metastron for metastatic bone cancer pain.
- Advances pre-clinical candidates for glaucoma, autism spectrum disorder, and liver cancer.
- Partners with other companies to develop new therapies.
- Provides resources to accelerate the development of acquired assets.
Modelo de Negocio
- Acquire or license promising drug candidates or technologies.
- Develop these assets through preclinical and clinical studies.
- Seek regulatory approval for new therapies.
- Commercialize approved products directly or through partnerships.
Contexto de la Industria
Q BioMed Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant clinical trial risks. The market for cancer therapeutics, particularly radiopharmaceuticals, is growing, driven by an aging population and increasing cancer incidence. The glaucoma and autism spectrum disorder markets also represent significant opportunities, but competition from established pharmaceutical companies and other biotech firms is intense. Q BioMed's success depends on its ability to efficiently develop and commercialize its pipeline assets in a cost-effective manner.
Clientes Clave
- Hospitals and oncology clinics using Strontium Chloride SR89 and Metastron.
- Patients suffering from metastatic bone cancer pain.
- Potential future patients with glaucoma, autism spectrum disorder, and liver cancer.
- Pharmaceutical companies interested in licensing or acquiring Q BioMed's assets.
Finanzas
Gráfico e información
Precio de la acción de Q BioMed Inc. (QBIO): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 19 feb 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· 1 oct 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para QBIO.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para QBIO.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de QBIO en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Denis D. Corin
CEO
Denis D. Corin serves as the CEO of Q BioMed Inc. His background includes experience in the life sciences and healthcare industries, with a focus on business development, strategic planning, and financial management. He has been involved in various aspects of the pharmaceutical and biotechnology sectors, including product development, licensing, and commercialization. His leadership is focused on driving the company's growth through strategic acquisitions and the advancement of its pipeline assets.
Historial: Under Denis D. Corin's leadership, Q BioMed Inc. has focused on acquiring and developing a portfolio of life science assets, including Strontium Chloride SR89 and Metastron. He has overseen the advancement of preclinical candidates such as Man-01 and QBM-001. Key strategic decisions have included partnerships and licensing agreements aimed at accelerating the development and commercialization of the company's products.
Información del mercado OTC de QBIO
The OTC Other tier represents the lowest tier of the OTC market, indicating that Q BioMed Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and potential for information asymmetry.
- Low trading volume and liquidity, increasing price volatility.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or trading suspension.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- FDA-approved products (Strontium Chloride SR89 and Metastron) indicate some level of regulatory compliance.
- Partnership with Mannin Research Inc. suggests external validation of the company's technology.
- Focus on developing therapies for unmet medical needs aligns with broader healthcare goals.
- Company has been in operation since 2013.
- Publicly traded status, even on the OTC market, requires some level of transparency.
Lo Que los Inversores Preguntan Sobre Q BioMed Inc. (QBIO)
¿Cuáles son los factores clave para evaluar QBIO?
Q BioMed Inc. (QBIO) actualmente tiene una puntuación IA de 57/100, indicando puntuación moderada. Fortaleza clave: Marketed products generating revenue (Strontium Chloride SR89 and Metastron).. Riesgo principal a monitorear: Ongoing: Limited financial resources and high cash burn rate.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de QBIO?
QBIO actualmente puntúa 57/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de QBIO?
Los precios de QBIO se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre QBIO?
La cobertura de analistas para QBIO incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en QBIO?
Las categorías de riesgo para QBIO incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Limited financial resources and high cash burn rate.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de QBIO?
La relación P/E para QBIO compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está QBIO sobrevalorada o infravalorada?
Determinar si Q BioMed Inc. (QBIO) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de QBIO?
Q BioMed Inc. (QBIO) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for OTC-listed companies.
- Financial data may not be fully up-to-date.
- AI analysis pending for QBIO.